Analysis of endometrial liquid‑based cytology samples to detect somatic mutations and classify ovarian cancer

Kubo‑Kaneda,Michiko; Kondo,Eiji; Nimura,Ryo; Okamoto,Kota; Matsumoto,Tsuyoshi; Yoshida,Kenta; Ikejiri,Makoto; Nakamura,Maki; Imai,Hiroshi; Okugawa,Yoshinaga; Nakatani,Kaname; Ikeda,Tomoaki

doi:10.3892/ol.2025.14866

Analysis of endometrial liquid‑based cytology samples to detect somatic mutations and classify ovarian cancer

Authors:
- Michiko Kubo‑Kaneda
- Eiji Kondo
- Ryo Nimura
- Kota Okamoto
- Tsuyoshi Matsumoto
- Kenta Yoshida
- Makoto Ikejiri
- Maki Nakamura
- Hiroshi Imai
- Yoshinaga Okugawa
- Kaname Nakatani
- Tomoaki Ikeda
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Mie University School of Medicine, Tsu, Mie 514‑8507, Japan, Department of Gynecologic Oncology, Cancer Institute Hospital, Tokyo 135‑8550, Japan, Department of Genomic Medicine, Mie University School of Medicine, Tsu, Mie 514‑8507, Japan, Department of Oncologic Pathology, Mie University School of Medicine, Tsu, Mie 514‑8507, Japan
Published online on: January 7, 2025 https://doi.org/10.3892/ol.2025.14866
Article Number: 119
Copyright : © Kubo‑Kaneda et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian cancer has a poor prognosis, and screening methods have not been established. Biomarkers based on molecular genetic characteristics must be identified to develop diagnostic and therapeutic strategies for all cancer types, particularly ovarian cancer. The present study aimed to evaluate the usefulness of genetic analysis of cervical and endometrial liquid‑based cytology (LBC) specimens for detecting somatic mutations in patients with ovarian cancer. The data of 19 patients with ovarian cancer treated between August 2019 and July 2022 were analyzed. LBC specimens from the cervix and endometrium of patients with preoperatively suspected ovarian cancer were collected, and genomic DNA was extracted from these LBC specimens and surgically removed cancer tissue sections for genetic analysis. Next‑generation sequencing (NGS) analysis of cervical and endometrial LBC revealed genetic mutations similar to those in formalin‑fixed, paraffin‑embedded (FFPE) tissues in 42% of ovarian cancer cases, including negative cervical and endometrial cytology cases and early‑stage cases. The pathogenic variants detected were PIK3CA (n=1), RB1 (n=1) and TP53 (n=6). In high‑grade serous carcinoma (HGSC) cases, the diagnosis rate was 54.5%, which was higher than that of other histological types. In univariate analysis of patients with HGSC, the presence of serous tubal intraepithelial carcinoma tended to be associated with the detection of somatic mutations in LBC samples. NGS analysis of cervical and endometrial LBC samples revealed genetic variants similar to those in FFPE tissues from ovarian cancer cases and may be useful as a noninvasive screening method for detecting somatic mutations and classifying ovarian cancer.

View Figures

View References

1	National Cancer Institute (NCI), . Cancer stat facts: Ovarian cancer. https://seer.cancer.gov/statfacts/html/ovary.htmlDecember 20–2024
2	Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, Amso NN, Apostolidou S, Benjamin E, Cruickshank D, et al: Ovarian cancer screening and mortality in the UK collaborative trial of ovarian cancer screening (UKCTOCS): A randomised controlled trial. Lancet. 387:945–956. 2016. View Article : Google Scholar : PubMed/NCBI
3	Menon U, Gentry-Maharaj A, Burnell M, Singh N, Ryan A, Karpinskyj C, Carlino G, Taylor J, Massingham SK, Raikou M, et al: Ovarian cancer population screening and mortality after long-term follow-up in the UK collaborative trial of ovarian cancer screening (UKCTOCS): A randomised controlled trial. Lancet. 397:2182–2193. 2021. View Article : Google Scholar : PubMed/NCBI
4	Rosenthal AN, Fraser LSM, Philpott S, Manchanda R, Burnell M, Badman P, Hadwin R, Rizzuto I, Benjamin E, Singh N, et al: Evidence of stage shift in women diagnosed with ovarian cancer during phase II of the United Kingdom familial ovarian cancer screening study. J Clin Oncol. 35:1411–1420. 2017. View Article : Google Scholar : PubMed/NCBI
5	Forstner R: Early detection of ovarian cancer. Eur Radiol. 30:5370–5373. 2020. View Article : Google Scholar : PubMed/NCBI
6	Thomassin-Naggara I, Poncelet E, Jalaguier-Coudray A, Guerra A, Fournier LS, Stojanovic S, Millet I, Bharwani N, Juhan V, Cunha TM, et al: Ovarian-Adnexal reporting data system magnetic resonance imaging (O-RADS MRI) score for risk stratification of sonographically indeterminate adnexal masses. JAMA Netw Open. 3:e19198962020. View Article : Google Scholar : PubMed/NCBI
7	Engbersen MP, Van Driel W, Lambregts D and Lahaye M: The role of CT, PET-CT, and MRI in ovarian cancer. Br J Radiol. 94:202101172021. View Article : Google Scholar : PubMed/NCBI
8	Cancer Genome Atlas Research Network, . Integrated genomic analyses of ovarian carcinoma. Nature. 474:609–615. 2011. View Article : Google Scholar : PubMed/NCBI
9	Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, et al: ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 363:1532–1543. 2010. View Article : Google Scholar : PubMed/NCBI
10	Kuo KT, Mao TL, Jones S, Veras E, Ayhan A, Wang TL, Glas R, Slamon D, Velculescu VE, Kuman RJ and Shih IM: Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol. 174:1597–1601. 2009. View Article : Google Scholar : PubMed/NCBI
11	Konecny GE, Wang C, Hamidi H, Winterhoff B, Kalli KR, Dering J, Ginther C, Chen HW, Dowdy S, Cliby W, et al: Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. J Natl Cancer Inst. 106:dju2492014. View Article : Google Scholar : PubMed/NCBI
12	Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, Fujiwara K, Vergote I, Colombo N, Mäenpää J, et al: Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 381:2416–2428. 2019. View Article : Google Scholar : PubMed/NCBI
13	Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, et al: Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 379:2495–2505. 2018. View Article : Google Scholar : PubMed/NCBI
14	Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, Normanno N, Scarpa A, Robson M, Meric-Bernstam F, et al: Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO precision medicine working group. Ann Oncol. 31:1491–1505. 2020. View Article : Google Scholar : PubMed/NCBI
15	Colombo N, Sessa C, Bois AD, Ledermann J, McCluggage WG, McNeish I, Morice P, Pignata S, Ray-Coquard I, Vergote I, et al: ESMO-ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Int J Gynecol Cancer. 2:ijgc-2019-000308. 2019.
16	Hirasawa T, Yasuda M, Muramatsu T, Itoh H, Shinozuka T, Makino T, Tsutsumi Y and Osamura RY: Cytologic study of ascites and the endometrium in ovarian carcinoma. Clinical significance. Acta Cytol. 41:1451–1455. 1997. View Article : Google Scholar : PubMed/NCBI
17	Wang Y, Li L, Douville C, Cohen JD, Yen TT, Kinde I, Sundfelt K, Kjær SK, Hruban RH, Shih IM, et al: Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. Sci Transl Med. 10:eaap87932018. View Article : Google Scholar : PubMed/NCBI
18	Akahane T, Yamaguchi T, Kato Y, Yokoyama S, Hamada T, Nishida Y, Higashi M, Nishihara H, Suzuki S, Ueno S and Tanimoto A: Comprehensive validation of liquid-based cytology specimens for next-generation sequencing in cancer genome analysis. PLoS One. 14:e02177242019. View Article : Google Scholar : PubMed/NCBI
19	Ab Mutalib NS, Syafruddin SE, Zain RR, Dali AZ, Yunos RI, Saidin S, Jamal R and Mokhtar NM: Molecular characterization of serous ovarian carcinoma using a multigene next generation sequencing cancer panel approach. BMC Res Notes. 7:8052014. View Article : Google Scholar : PubMed/NCBI
20	Watanabe T, Nanamiya H, Kojima M, Nomura S, Furukawa S, Soeda S, Tanaka D, Isogai T, Imai JI, Watanabe S and Fujimori K: Clinical implication of oncogenic somatic mutations in early-stage cervical cancer with radical hysterectomy. Sci Rep. 10:187342020. View Article : Google Scholar : PubMed/NCBI
21	Watanabe T, Nanamiya H, Endo Y, Kojima M, Nomura S, Furukawa S, Soeda S, Tamura H, Ryufuku M, Tanaka D, et al: Identification and clinical significance of somatic oncogenic mutations in epithelial ovarian cancer. J Ovarian Res. 14:1292021. View Article : Google Scholar : PubMed/NCBI
22	Schneider G, Schmidt-Supprian M, Rad R and Saur D: Tissue-specific tumorigenesis: Context matters. Nat Rev Cancer. 17:239–253. 2017. View Article : Google Scholar : PubMed/NCBI
23	Nimura R, Kondo E, Yoshida K, Kubo-Kaneda M, Nii M, Ikeijiri M, Nakamura M, Imai H, Okugawa Y, Nakatani K and Ikeda T: Cancer-associated gene analysis of cervical cytology samples and liquid-based cytology significantly improve endometrial cancer diagnosis sensitivity. Oncol Lett. 24:3762022. View Article : Google Scholar : PubMed/NCBI
24	Matsuura M, Yamaguchi K, Tamate M, Satohisa S, Teramoto M, Iwasaki M, Sugita S, Hasegawa T, Koubo R, Takane K, et al: Efficacy of liquid-based genetic diagnosis of endometrial cancer. Cancer Sci. 109:4025–4032. 2018. View Article : Google Scholar : PubMed/NCBI
25	Akahane T, Kitazono I, Kobayashi Y, Nishida-Kirita Y, Yamaguchi T, Yanazume S, Tabata K, Kobayashi H and Tanimoto A: Direct next-generation sequencing analysis using endometrial liquid-based cytology specimens for rapid cancer genomic profiling. Diagn Cytopathol. 49:1078–1085. 2021. View Article : Google Scholar : PubMed/NCBI
26	Hirasawa A, Imoto I, Naruto T, Akahane T, Yamagami W, Nomura H, Masuda K, Susumu N, Tsuda H and Aoki D: Prevalence of pathogenic germline variants detected by multigene sequencing in unselected Japanese patients with ovarian cancer. Oncotarget. 8:112258–112267. 2017. View Article : Google Scholar : PubMed/NCBI
27	Žilovič D, Vaicekauskaitė I, Čiurlienė R, Sabaliauskaitė R and Jarmalaitė S: Uterine cavity lavage mutation analysis in lithuanian ovarian cancer patients. Cancers (Basel). 15:8682023. View Article : Google Scholar : PubMed/NCBI
28	SEER*Explorer, . An interactive website for SEER cancer statistics. Surveillance Research Program, National Cancer Institute; 2024, https://seer.cancer.gov/statistics-network/explorer/application.html?site=61&data_type=1&graph_type=2&compareBy=race&chk_race_6=6&chk_race_5=5&chk_race_4=4&chk_race_9=9&chk_race_8=8&rate_type=2&hdn_sex=3&age_range=1&stage=101&advopt_precision=1&advopt_show_ci=on&hdn_view=0&advopt_show_apc=on&advopt_display=2#resultsRegion0December 20–2024
29	Yokoi A, Matsuzaki J, Yamamoto Y, Yoneoka Y, Takahashi K, Shimizu H, Uehara T, Ishikawa M, Ikeda SI, Sonoda T, et al: Integrated extracellular microRNA profiling for ovarian cancer screening. Nat Commun. 9:43192018. View Article : Google Scholar : PubMed/NCBI